Shares of Emergent Biosolutions Inc. (NYSE:EBS) reached a new 52-week low on Friday . The company traded as low as $26.76 and last traded at $26.77, with a volume of 273,184 shares. The stock had previously closed at $27.60.

A number of research firms recently commented on EBS. Chardan Capital began coverage on shares of Emergent Biosolutions in a research note on Friday, April 15th. They set a “buy” rating and a $47.00 price target for the company. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research note on Wednesday, June 22nd. Zacks Investment Research cut shares of Emergent Biosolutions from a “hold” rating to a “sell” rating in a research note on Tuesday, June 28th. Singular Research lowered their price objective on shares of Emergent Biosolutions from $44.00 to $40.00 and set a “buy” rating for the company in a research report on Tuesday, June 28th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Emergent Biosolutions from $45.00 to $36.00 and set an “overweight” rating for the company in a research report on Friday, August 5th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $40.00.

The firm has a 50 day moving average of $30.41 and a 200 day moving average of $36.12. The firm has a market capitalization of $1.09 billion and a PE ratio of 19.22.

Emergent Biosolutions (NYSE:EBS) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by $0.01. During the same period in the prior year, the business posted $0.36 EPS. The firm earned $101.49 million during the quarter, compared to the consensus estimate of $111.20 million. The company’s revenue was down 19.5% on a year-over-year basis. Equities analysts expect that Emergent Biosolutions Inc. will post $0.89 earnings per share for the current fiscal year.

In other Emergent Biosolutions news, Director Jerome M. Hauer sold 3,134 shares of the stock in a transaction on Thursday, May 19th. The stock was sold at an average price of $41.22, for a total value of $129,183.48. Following the sale, the director now directly owns 20,085 shares of the company’s stock, valued at $827,903.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director George A. Joulwan sold 4,700 shares of the stock in a transaction on Monday, June 6th. The stock was sold at an average price of $44.12, for a total value of $207,364.00. Following the completion of the sale, the director now directly owns 20,785 shares in the company, valued at $917,034.20. The disclosure for this sale can be found here.

Other large investors recently modified their holdings of the company. US Bancorp DE raised its stake in shares of Emergent Biosolutions by 6.9% in the fourth quarter. US Bancorp DE now owns 33,169 shares of the biopharmaceutical company’s stock valued at $1,327,000 after buying an additional 2,152 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Emergent Biosolutions by 6.4% in the fourth quarter. Rhumbline Advisers now owns 41,899 shares of the biopharmaceutical company’s stock valued at $1,676,000 after buying an additional 2,505 shares in the last quarter. Cornerstone Capital Management Holdings LLC. raised its position in shares of Emergent Biosolutions by 5.9% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 57,927 shares of the biopharmaceutical company’s stock worth $2,317,000 after buying an additional 3,227 shares during the period. Bank of Montreal Can raised its position in shares of Emergent Biosolutions by 346.9% in the fourth quarter. Bank of Montreal Can now owns 93,100 shares of the biopharmaceutical company’s stock worth $3,725,000 after buying an additional 72,266 shares during the period. Finally, California Public Employees Retirement System raised its position in shares of Emergent Biosolutions by 5.1% in the fourth quarter. California Public Employees Retirement System now owns 104,000 shares of the biopharmaceutical company’s stock worth $4,161,000 after buying an additional 5,000 shares during the period.

Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.